EMA accepts Sandoz’s pegfilgrastim submission

February 15, 2016 11:49 AM

Sandoz, announced that EMA has accepted their Marketing Authorization Application for its biosimilar to Amgen’s EU-licensed Neulasta (pegfilgrastim) – a long-acting recombinant human granulocyte colony-stimulating factor (G-CSF).

Sandoz is seeking approval for the same indication as the reference product.

Commenting on this milestone, Richard Francis, Division Head and CEO Sandoz said, “Securing five major regulatory file acceptances in five months demonstrates substantial progress on our long-term biosimilars investment strategy. Further advancing our biosimilars pipeline is an important priority for us this year and we’ll continue to invest significantly in bringing our pipeline to patients.”

Pegfilgrastim is a prescription medicine used in cancer patients (except those with chronic myeloid leukemia and myelodysplastic syndromes) to help with some of the side effects of their treatment. It reduces the duration of neutropenia and the incidence of febrile neutropenia that are a result of their chemotherapy treatment. The incidence of febrile neutropenia occurring with common chemotherapy regimens is 25 to 40% of treatment-naive patients.

“Sandoz is the leading provider of daily G-CSF in Europe and the regulatory filing of our biosimilar pegfilgrastim further cements our commitment to patients undergoing cancer treatment” said Mark McCamish, M.D., Ph.D., and Head of Global Biopharmaceutical & Oncology Injectables Development at Sandoz.  “If approved, physicians in the EU will have another high-quality Sandoz biosimilar treatment option for patients needing granulocyte colony-stimulating factors” McCamish continued.

Sandoz believes that the totality of evidence in its submission, including three pivotal clinical trials – one pharmacokinetic and pharmacodynamic study in healthy volunteers and two comparative efficacy and safety studies in breast cancer patients – is expected to satisfy the regulatory requirements for demonstrating high similarity to the reference product and therefore justifies use of biosimilar pegfilgrastim in the reference product’s indication.

Sandoz currently markets three biosimilars and has a pipeline with several biosimilars in late stage development, including assets in oncology. Pegfilgrastim was recently accepted by the FDA for regulatory filing, making this announcement the fifth of 10 that the company plans to make over a three-year period (2015-2017).

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!